Valeant Pharmaceuticals NYSE:VRX acting CFO and board member Philip Loberg purchased 7,500 shares on June 9 for a total purchase of $396,150. Loberg bought shares ahead of an expected FDA decision on an epileptic seizure drug, Potiga. This drug was approved for limited use on June 13.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company’s specialty pharmaceutical and over-the-counter (OTC) products are marketed under brand names and are sold in the United States, Canada, Australia and New Zealand. The Company also has branded generic and OTC operations in Europe and Latin America, which focus on pharmaceutical products that are bioequivalent to original products and are marketed under company brand names.

On March 10, 2011, the Company acquired PharmaSwiss S.A. On February 9, 2011, the Company acquired the Canadian rights to Cholestagel, an oral bile acid sequestrant for hypercholesterolemia, from Genzyme Corporation. On February 7, 2011, the Company entered into an agreement to license the Canadian rights to ACZONE Gel 5%, a topical formulation of dapsone used in the treatment of acne vulgaris, from Allergan, Inc. On October 29, 2010, it acquired several privately-owned pharmacy skin care brands in Australia. The brands include Hamilton’s Suncare and Hamilton’s Skin Therapy. On September 28, 2010, the Company completed the acquisition of Valeant Pharmaceuticals International (Valeant). In May 2010, Valeant completed the acquisition of Aton Pharma, Inc. On March 25, 2010, it acquired certain AMPAKINE compounds from Cortex Pharmaceuticals, Inc. (Cortex) for use in the field of respiratory depression, a brain-mediated breathing disorder.

For the rest of the article click here